Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous plerixafor for stem cell mobilization in HLA-identical sibling donors
NL-OMON41565Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 5 more, sponsored by HOVON. Primary endpoint: Successful harvest rate. Started Sep 2011; status: active, not recruiting.
02
Drugs
plerixafor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON41565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41565.